The trial will be conducted in the Democratic Republic of the Congo in partnership with Emergent BioSolutions.

Emergent BioSolutions' Q3 earnings report drives 20% surge in share price, reflecting market optimism. See why award a ...

Shares of Emergent Biosolutions climbed after the company reported an increase in revenue and swung to a profit in the third quarter. The stock was up 28% to $11.81 in Thursday afternoon trading.

Emergent BioSolutions raised its revenue guidance and dropped a going concern warning. Its CEO is billing this next chapter ...

European shares closed mostly higher today. The eurozone's STOXX 600 gained 0.62%, Germany's DAX gained 1.70% and France's CAC 40 rose 0.76%. Spain's IBEX 35 Index rose 0.65%, while London's FTSE 100 ...

Concurrently, Emergent BioSolutions announced that brincidofovir (brand name Tembexa for smallpox treatment) will be included ...

Emergent BioSolutions (EBS) announced that brincidofovir will be included in a clinical trial conducted and sponsored by Panther, under the ...

Emergent Biosolutions (EBS) came out with quarterly earnings of $1.37 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to loss of $1.44 per share a year ago. These ...

PANTHER to conduct clinical trial under the leadership of Africa Centres for Disease Control and PreventionGAITHERSBURG, Md., Nov. 06, 2024 ...

Emergent Biosolutions (EBS) stock rose 14% post-market after the company raised the lower end of its revenue guidance range ...

Inventus Mining Corp. (TSX VENTURE: IVS) ("Inventus” or the "Company”) is pleased to report that it has closed the previously announced non-brokered private placement of 15,000,000 units of the ...

Emergent BioSolutions appointed Dr. Simon Lowry as chief medical officer and head of research and development. CureVac named ...